A carregar...
Publicação
Prognostic role of secreted YB-1 in patients with breast cancer
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 982.06 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Y box binding protein 1 (YBX1 ou YB-1) é um membro da família de factores de transcrição YBX, codificado pelo gene YBX1. Esta proteína está associada à carcinogénese, proliferação e progressão tumoral e, no caso específico do cancro da mama, está relacionada com um pior prognóstico. No entanto, a função da sua forma secretada (sYB-1) é ainda desconhecida. Num estudo anterior observámos existir uma correlação entre a detecção de sYB-1 no soro de doentes com cancro da mama em estadio avançado, o desenvolvimento de metástases extra-ósseas, e uma mais rápida progressão da doença óssea. Neste estudo caso-controlo pretendemos avaliar a associação entre a detecção de sYB-1 e os outcomes clínicos em cancro da mama em estadio inicial. A sYB-1 foi quantificada por ELISA num cohort de 80 amostras de soro de doentes incluídos no estudo AZURE, igualmente distribuídos em função da recorrência ou não nos primeiros cinco anos de follow-up após inclusão no estudo. Avaliámos a associação com os outcomes clínicos e características demográficas e clinico-patológicas dos doentes.
A detecção de sYB1 foi mais frequente em doentes sem recorrência (p=0.0024), e em doentes com metástases viscerais no caso dos que recidivaram (p=0.0436). Desta forma a sYB-1 parece ser um indicador de bom prognóstico, estando associada a maior sobrevivência global (p=0,0129) e sobrevivência livre de doença (p=0,0099). Estes resultados sugerem que a sYB-1 pode reflectir uma resposta imune protectora nesta fase inicial da doença. É necessário validar estes resultados num cohort alargado de doentes e compreender o verdadeiro significado prognóstico de sYB-1 em cancro da mama.
Y box binding protein 1 (YBX1 or YB-1) is a member of the YBX family of transcription factors, encoded by the YBX1 gene. It has been associated with carcinogenesis, tumour proliferation and dissemination and in the specific case of breast cancer it is closely related with poor prognosis. However, the role of its secreted form (sYB-1) remains undetermined. In a previous study we have found a significant correlation between detectable sYB-1, development of extra-bone metastases and faster bone disease progression, in patients with advanced breast cancer. In this case-control study the aim was to assess the association between sYB-1 positivity and clinical outcomes in early breast cancer. sYB-1 was quantified by ELISA in serum samples from patients enrolled in the AZURE trial, equally divided between no recurrence and relapse within five years of enrolment. Association with clinical outcomes and patient demographics and clinicopathologic characteristics was evaluated. Positive sYB1 was associated with no recurrence (p=0.0024), and with visceral relapse in patients who recurred (p=0.0436). sYB-1 was an indicator of good prognosis, reflected in higher overall survival (OS) (p=0,0129) and relapse-free survival (RFS) (p=0,0099). These results suggest that sYB-1 might be involved in a protective immune response in early stage disease. Further investigation is needed to validate these results and to better understand of the prognostic role of sYB-1 in early and advanced disease.
Y box binding protein 1 (YBX1 or YB-1) is a member of the YBX family of transcription factors, encoded by the YBX1 gene. It has been associated with carcinogenesis, tumour proliferation and dissemination and in the specific case of breast cancer it is closely related with poor prognosis. However, the role of its secreted form (sYB-1) remains undetermined. In a previous study we have found a significant correlation between detectable sYB-1, development of extra-bone metastases and faster bone disease progression, in patients with advanced breast cancer. In this case-control study the aim was to assess the association between sYB-1 positivity and clinical outcomes in early breast cancer. sYB-1 was quantified by ELISA in serum samples from patients enrolled in the AZURE trial, equally divided between no recurrence and relapse within five years of enrolment. Association with clinical outcomes and patient demographics and clinicopathologic characteristics was evaluated. Positive sYB1 was associated with no recurrence (p=0.0024), and with visceral relapse in patients who recurred (p=0.0436). sYB-1 was an indicator of good prognosis, reflected in higher overall survival (OS) (p=0,0129) and relapse-free survival (RFS) (p=0,0099). These results suggest that sYB-1 might be involved in a protective immune response in early stage disease. Further investigation is needed to validate these results and to better understand of the prognostic role of sYB-1 in early and advanced disease.
Descrição
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2019
Palavras-chave
YB-1 secretada Biomarcador prognóstico Imunidade anti-tumoral Neoplasias da mama Oncobiologia